ArticleRSC advances2026
CPB@PLH NPs accelerate wound healing by antibacterial and anti-inflammatory effects.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic wounds are a severe complication of diabetes, with their non-healing nature closely associated with infection, oxidative stress, and the inflammatory microenvironment. To address the limited therapeutic efficacy of conventional antibiotics, which often lead to drug resistance and offer functionality, this study constructed a multifunctional composite nano-platform (CPB@PLH NPs) based on carboxylated Prussian blue nanoparticles (CPB NPs) and a novel antimicrobial peptide of PLH054001130. This platform integrates the broad-spectrum antimicrobial and biofilm-disrupting capabilities of PLH with the antioxidant and anti-inflammatory functions of CPB NPs, enabling synergistic "anti-bacteria-anti-inflammation" therapy.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.